Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

Aripiprazols sikkerhed og effekt i langsigtet vedligeholdelsesbehandling af pædiatriske patienter med irritabilitet forbundet med autistisk lidelse

The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

215

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Dothan, Alabama, Forenede Stater, 36303
        • Harmonex Neuroscience Research, Inc
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85006
        • Southwest Autism Research And Resource Center
    • California
      • Costa Mesa, California, Forenede Stater, 92626
        • Clinical Innovations, Inc.
      • Glendale, California, Forenede Stater, 91206
        • Behavioral Research Specialists, Llc
      • Palo Alto, California, Forenede Stater, 94306
        • Abbey Neuropsychology Clinic
      • San Francisco, California, Forenede Stater, 94143
        • Ucsf - Lppi
      • Stanford, California, Forenede Stater, 94305
        • Stanford University School Of Medicine
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • Children'S National Medical Center
    • Florida
      • Gainesville, Florida, Forenede Stater, 32607
        • Sarkis Clinical Trials
      • Hialeah, Florida, Forenede Stater, 33012
        • Palm Springs Research Institute
      • Maitland, Florida, Forenede Stater, 32751
        • Florida Clinical Research Center, Llc
      • Miami, Florida, Forenede Stater, 33155
        • Miami Children'S Hospital
      • Tampa, Florida, Forenede Stater, 33613
        • University Of South Florida
    • Georgia
      • Smyrna, Georgia, Forenede Stater, 30080
        • Institute For Behavioral Medicine, Llc
    • Idaho
      • Coeur d'Alene, Idaho, Forenede Stater, 83814
        • Kootenai Behavioral Health Center
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40202
        • Kosair Charities Pediatric Clinical Research Unit
    • Louisiana
      • Shreveport, Louisiana, Forenede Stater, 71103
        • Lsu Health Sciences Center
    • Massachusetts
      • Newton, Massachusetts, Forenede Stater, 02459
        • Neurocare, Inc.
    • Michigan
      • Bloomfield Hills, Michigan, Forenede Stater, 48302
        • Neurobehavioral Medicine Group
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89128
        • Center For Psychiatry And Behavioral Medicine, Inc
    • New Jersey
      • Gibbsboro, New Jersey, Forenede Stater, 08026
        • Clinical Research Center Of New Jersey
      • Toms River, New Jersey, Forenede Stater, 08755
        • Children'S Specialized Hosp
    • New York
      • Stony Brook, New York, Forenede Stater, 11794
        • Stony Brook University School Of Medicine
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27517
        • Unc Chapel Hill
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • University Hospitals Case Medical Center
      • Cleveland, Ohio, Forenede Stater, 44104
        • Cleveland Clinic
      • Columbus, Ohio, Forenede Stater, 43210
        • The Ohio State University Nisonger Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73116
        • Cutting Edge Research Group
      • Oklahoma City, Oklahoma, Forenede Stater, 73117
        • Ou Physician'S Child Study Center
      • Tulsa, Oklahoma, Forenede Stater, 74104
        • Tulsa Clinical Research, Llc
    • Oregon
      • Gresham, Oregon, Forenede Stater, 97030
        • Cyn3rgy Research
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19124
        • Drexel University College Of Medicine
      • Pittsburgh, Pennsylvania, Forenede Stater, 15203
        • Western Psychiatric Institute And Clinic
    • Tennessee
      • Kingsport, Tennessee, Forenede Stater, 37660
        • Holston Medical Group
    • Texas
      • DeSoto, Texas, Forenede Stater, 75115
        • Insite Clinical Research
    • Utah
      • Clinton, Utah, Forenede Stater, 84015
        • Ericksen Research And Development
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23510
        • Childrens Specialty Gr., Pllc
      • Richmond, Virginia, Forenede Stater, 23298
        • Virginia Treatment Center For Children

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 år til 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
  • Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
  • Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
  • Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
  • An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
  • Mental age of at least 24 months

Key Exclusion Criteria:

  • Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
  • Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
  • Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
  • Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
  • History of neuroleptic malignant syndrome
  • At significant risk for suicide based on history or routine psychiatric status examination
  • A seizure within the past year
  • History of severe head trauma or stroke
  • History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
  • Weight lower than 15 kg
  • Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
  • History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
  • Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Tablets, oral, 0 mg, once daily, 16 weeks

Eksperimentel: Aripiprazol

Tablets, oral, 2-15 mg, once daily, 13-42 weeks

Andre navne:
  • Abilify
  • BMS-337039

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Patients Relapsing by Week 16
Tidsramme: From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment.

From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
Tidsramme: From Baseline (end of Phase 1) to Week 16 of Phase 2

ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
Tidsramme: From Baseline (end of Phase 1) to Week 16 of Phase 2

CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
Tidsramme: Up to 26 weeks

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Up to 26 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
Tidsramme: Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. marts 2011

Primær færdiggørelse (Faktiske)

20. juni 2012

Studieafslutning (Faktiske)

20. juni 2012

Datoer for studieregistrering

Først indsendt

22. oktober 2010

Først indsendt, der opfyldte QC-kriterier

22. oktober 2010

Først opslået (Anslået)

25. oktober 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CN138-603

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .